NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis $11.83 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.55▼$12.3750-Day Range$10.41▼$16.4652-Week Range$8.51▼$17.79Volume608,516 shsAverage Volume819,256 shsMarket Capitalization$661.70 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Olema Pharmaceuticals alerts: Email Address Olema Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside128.2% Upside$27.00 Price TargetShort InterestBearish15.34% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingSelling Shares$36.12 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.51) to ($2.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector680th out of 910 stocksPharmaceutical Preparations Industry314th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingOlema Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.34% of the outstanding shares of Olema Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 6.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OLMA. Previous Next 1.3 News and Social Media Coverage News SentimentOlema Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Olema Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -91% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,124,048.00 in company stock.Percentage Held by Insiders19.40% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($1.51) to ($2.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -5.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 2.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Olema Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Olema Pharmaceuticals Stock (NASDAQ:OLMA)Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Read More OLMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OLMA Stock News HeadlinesAugust 7, 2024 | insidertrades.comInsider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Sells 2,400,000 Shares of StockSeptember 4 at 4:49 PM | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 28, 2024 | americanbankingnews.comBrokerages Set Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Price Target at $27.00August 21, 2024 | globenewswire.comOlema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 7, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals Based on Promising Clinical Data and Strategic Drug PositioningAugust 7, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)August 7, 2024 | markets.businessinsider.comBuy Rating Affirmed: Promising Clinical Trial Results and Future Prospects for Olema PharmaceuticalsSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic CollaborationsAugust 6, 2024 | globenewswire.comOlema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | finance.yahoo.comOLMA Aug 2024 12.500 call (OLMA240816C00012500)July 25, 2024 | investing.comOlema Pharmaceuticals Inc (OLMA)July 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17, 2024 | seekingalpha.comOlema Pharmaceuticals: Still Merits A Small HoldingJune 4, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 28, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferences in JuneSee More Headlines Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OLMA CUSIPN/A CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$31.00 Low Stock Price Target$20.00 Potential Upside/Downside+128.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.18% Return on Assets-40.30% Debt Debt-to-Equity RatioN/A Current Ratio9.13 Quick Ratio9.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book2.57Miscellaneous Outstanding Shares55,934,000Free Float45,083,000Market Cap$661.70 million OptionableOptionable Beta2.03 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Sean P. Bohen M.D. (Age 57)Ph.D., President, CEO & Director Comp: $1.15MMr. Shane William Charles Kovacs M.B.A. (Age 50)Chief Operating & Financial Officer Comp: $820.37kDr. Naseem Zojwalla M.D. (Age 51)Chief Medical Officer Comp: $753.37kMs. Julie DexterSenior VP & Head of PeopleDr. David C. Myles Ph.D. (Age 61)Chief Discovery & Non-Clinical Development Officer Comp: $200kMs. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMr. John B. Moriarty Jr. (Age 56)ESQ., J.D., Corporate Secretary Comp: $434.32kMs. Sasha Austin CPAVP of Finance & ControllerMore ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXJanux TherapeuticsNASDAQ:JANXCatalyst PharmaceuticalsNASDAQ:CPRXAmphastar PharmaceuticalsNASDAQ:AMPHVerona PharmaNASDAQ:VRNAView All CompetitorsInsiders & InstitutionsDana Investment Advisors Inc.Bought 74,657 shares on 8/27/2024Ownership: 0.133%Affinity Asset Advisors LLCBought 275,000 shares on 8/15/2024Ownership: 0.492%Deerfield Management Company L.P. Series CBought 31,405 shares on 8/15/2024Ownership: 0.056%Susquehanna Portfolio Strategies LLCSold 8,059 shares on 8/15/2024Ownership: 0.047%The Manufacturers Life Insurance Company Bought 5,449 shares on 8/15/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions OLMA Stock Analysis - Frequently Asked Questions How have OLMA shares performed this year? Olema Pharmaceuticals' stock was trading at $14.03 at the beginning of the year. Since then, OLMA shares have decreased by 15.7% and is now trading at $11.83. View the best growth stocks for 2024 here. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) announced its earnings results on Tuesday, August, 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.54). When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Top institutional shareholders of Olema Pharmaceuticals include Point72 Asset Management L.P. (5.61%), Logos Global Management LP (5.74%), Dimensional Fund Advisors LP (3.01%) and Candriam S.C.A. (1.89%). Insiders that own company stock include Bvf Partners L P/Il, G Walmsley Graham, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Naseem Zojwalla and Kinney Horn. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OLMA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.